Ignite Creation Date:
2025-12-25 @ 4:57 AM
Ignite Modification Date:
2025-12-26 @ 3:57 AM
Study NCT ID:
NCT06728618
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-12-11
First Post:
2024-12-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
Sponsor:
Organization: